Register
FDA approves pembrolizumab for advanced Merkel Cell Carcinoma |
Clinical News
eMediNexus Coverage from: 
FDA approves pembrolizumab for advanced Merkel Cell Carcinoma

0 Read Comments                

The US Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda, Merck), a programmed cell death–ligand-1 (PD-L1) inhibitor, for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now